Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations.

Abstract excerpt

While immune checkpoint inhibitors have transformed treatment for many cancers, their benefit remains limited across all tumor types and is constrained by immune-related toxicity. Targeted immunotherapies, including T-cell engagers (TCEs), offer a more selective strategy by directing immune activity toward tumor-associated antigens. TCEs have achieved major success in hematologic malignancies and now show promise...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Bispecific
• Share to Antineoplastic Agents, Immunological